AU733415B2 - Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals - Google Patents

Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals Download PDF

Info

Publication number
AU733415B2
AU733415B2 AU80685/98A AU8068598A AU733415B2 AU 733415 B2 AU733415 B2 AU 733415B2 AU 80685/98 A AU80685/98 A AU 80685/98A AU 8068598 A AU8068598 A AU 8068598A AU 733415 B2 AU733415 B2 AU 733415B2
Authority
AU
Australia
Prior art keywords
attached
substituted
catalyst
carbon
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU80685/98A
Other languages
English (en)
Other versions
AU8068598A (en
Inventor
Daniela Salvemini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU8068598A publication Critical patent/AU8068598A/en
Application granted granted Critical
Publication of AU733415B2 publication Critical patent/AU733415B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
AU80685/98A 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals Ceased AU733415B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5040297P 1997-06-20 1997-06-20
US60/050402 1997-06-20
PCT/US1998/012231 WO1998058636A1 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Publications (2)

Publication Number Publication Date
AU8068598A AU8068598A (en) 1999-01-04
AU733415B2 true AU733415B2 (en) 2001-05-17

Family

ID=21965044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80685/98A Ceased AU733415B2 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Country Status (12)

Country Link
US (2) US6180620B1 (enExample)
EP (1) EP1001752B1 (enExample)
JP (1) JP2002506445A (enExample)
AT (1) ATE256467T1 (enExample)
AU (1) AU733415B2 (enExample)
CA (1) CA2294155A1 (enExample)
DE (1) DE69820633T2 (enExample)
DK (1) DK1001752T3 (enExample)
ES (1) ES2215305T3 (enExample)
PT (1) PT1001752E (enExample)
WO (1) WO1998058636A1 (enExample)
ZA (1) ZA985376B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
ATE552260T1 (de) * 1999-01-25 2012-04-15 Nat Jewish Health Substituierte porphyrine und deren therapeutische verwendung
AU5048400A (en) 1999-05-27 2000-12-18 Monsanto Company Biomaterials modified with superoxide dismutase mimics
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20050175580A1 (en) * 2001-01-05 2005-08-11 Daniela Salvemini Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
ATE439134T1 (de) * 2001-01-19 2009-08-15 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
WO2002058686A2 (en) * 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
EP1405066B1 (en) * 2001-03-02 2015-06-17 Galera Therapeutics LLC Chromatography of metal complexes
US20040137638A1 (en) * 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
AU2002312194B8 (en) * 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
AU2002315001A1 (en) * 2001-06-08 2002-12-23 Metaphore Pharmaceuticals, Inc. Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
JP2005519852A (ja) * 2001-06-26 2005-07-07 メタファー・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の予防および／または処置のためのＳＯＤｍとコルチコステロイドの組合せ療養
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
PT1463563E (pt) * 2001-12-14 2009-03-19 Alcon Inc Miméticos de dismutase do superóxido para o tratamento de distúrbios e doenças oculares
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
EP1513537A4 (en) * 2002-06-07 2006-09-06 Univ Duke Substituted porphyrins
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
CN1717234A (zh) * 2002-12-06 2006-01-04 爱尔康公司 用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物
KR100648618B1 (ko) * 2003-11-19 2006-11-23 주식회사 웰스킨 활성 산소 억제제
KR20060101501A (ko) * 2003-12-11 2006-09-25 알콘, 인코퍼레이티드 시신경 및 망막 손상의 치료를 위한 슈퍼옥사이드디스무타제 유사체
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006069326A2 (en) * 2004-12-21 2006-06-29 Metaphore Pharmaceuticals, Inc. Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
EP2056675B1 (en) * 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
WO2009065059A2 (en) 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
EP2732817B1 (en) 2008-05-23 2016-08-24 National Jewish Health A compound for use in treating injury associated with exposure to phosgene or chlorine gas
WO2013048965A1 (en) 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment
AU2017318718B2 (en) 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
CA3053779A1 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2021163397A1 (en) 2020-02-13 2021-08-19 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof
WO2025024390A2 (en) * 2023-07-21 2025-01-30 Galera Labs, Llc Carcinogenesis reduction with pentaaza macrocyclic ring complex

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4999347A (en) 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
DE69224839T2 (de) 1991-07-19 1998-10-08 Monsanto Co Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
IL125889A0 (en) 1996-03-13 1999-04-11 Monsanto Co Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
ATE256467T1 (de) 2004-01-15
DK1001752T3 (da) 2004-04-19
DE69820633D1 (de) 2004-01-29
DE69820633T2 (de) 2004-09-23
CA2294155A1 (en) 1998-12-30
WO1998058636A1 (en) 1998-12-30
AU8068598A (en) 1999-01-04
EP1001752A1 (en) 2000-05-24
EP1001752B1 (en) 2003-12-17
US6395725B1 (en) 2002-05-28
ZA985376B (en) 1999-06-21
ES2215305T3 (es) 2004-10-01
PT1001752E (pt) 2004-05-31
JP2002506445A (ja) 2002-02-26
US6180620B1 (en) 2001-01-30

Similar Documents

Publication Publication Date Title
AU733415B2 (en) Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
PL146301B1 (en) Method of obtaining phenyl carbaminates
JP2012097097A (ja) スーパーオキシドジスムターゼ活性を有する置換型ピリジノペンタアザ大環錯体
PL185189B1 (pl) 2,4-disulfonylo-fenylo-butylonitron, jego sole oraz zawierające je środki farmaceutyczne
KR19990087113A (ko) 약품으로 인한 독성을 경감할 수 있는 산화질소 도너
Nurchi et al. A new tripodal kojic acid derivative for iron sequestration: Synthesis, protonation, complex formation studies with Fe3+, Al3+, Cu2+ and Zn2+, and in vivo bioassays
US20040147498A1 (en) Combinations of superoxide dismutase mimetics and nonsteroidal analgesic / anti-inflammatory drugs
EP1322654B1 (en) Platinum complexes as antitumour agents
RU2130941C1 (ru) Трехъядерные катионные комплексы платины, проявляющие противоопухолевую активность, способ их получения и фармацевтические композиции, содержащие эти комплексы
AU613720B2 (en) Platinum chemotherapeutic product
DE68928968T2 (de) Metall-organische kobalt-verbindungen und deren verwendungen
AU2005323534A1 (en) Analgesic conjugates
US20050032801A1 (en) Compositions containing a ruthenium(III) complex and a heterocycle
CA2187794A1 (en) Benzamide-containing pharmaceutical compositions
US3962447A (en) Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and method of using same
RU96119798A (ru) Трехъядерные катионные комплексы платины, обладающие противоопухолевой активностью, и фармацевтические композиции, содержащие эти комплексы
WO2001076569A2 (en) An improved pt(iv) antitumor agent
US4843161A (en) Platinum-intercalative complexes for the treatment of cancer
US20050171198A1 (en) SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
JPH10509159A (ja) 抗腫瘍活性を有する三核性カチオン性プラチナ錯体、及びそれらを含有する医薬組成物
KR20000069028A (ko) 피리도스티그민의 다가염 및 관련 화합물
US4165380A (en) Bis(sulfide)gold(1+) salts
US5142076A (en) Metallo-organic salt compounds and pharmaceutical uses thereof
WO2008121322A1 (en) A method of treating neuroblastoma
EP1414830B1 (de) Tumorhemmende lanthanverbindungen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)